Personalized therapy in pediatric nephrology: Problems and prospects
https://doi.org/10.21508/1027-4065-2021-66-2-6-12
Abstract
The term “personalized medicine” appeared only 20 years ago, but individual approaches to the therapy were known for more than a hundred years. The genome decoding and development of pharmacogenetics in recent decades have opened up new ways for the development of medicine and a new understanding of the concept of “personalized medicine”. The article uses the example of nephrological diseases (Denis–Drash syndrome, Freiser syndrome, hypophosphatemic rickets, nephrotic syndrome) to demonstrate the importance of molecular genetic examination and to improve the effectiveness of treatment and, most importantly, to prevent iatrogenic side effects of the therapy. The example of glucocorticoid therapy of children with nephrotic syndrome is used to demonstrate the importance of studying certain genetic factors that affect the individual pharmacodynamic and pharmacokinetic profile of glucocorticosteroids.
Keywords
Supporting agencies: The article was written under funding Gostaria the Ministry of health «Clinical and molecular genetic criteria for predicting the effectiveness of steroid and immunosuppressive therapy of primary nephrotic syndrome in children» №2 00 080 056.
About the Authors
V. V. Dlin
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
S. L. Morozov
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
References
1. Ginsburg G.S., Willard H.F. Genomic and personalized medicine: foundations and applications. Translational Res 2009; 154(6): 277–287. DOI: 10.1016/j.trsl.2009.09.005
2. Приказ Министерства здравоохранения РФ от 24 апреля 2018 г. за No186 «Об утверждении Концепции предиктивной, превентивной и персонализированной медицины». [Order of the Ministry of Health of the Russian Federation of April 24, 2018 for N186 «On approval of the Concept of pre- dictive, preventive and personalized medicine». (In Russ.)] https://webmed.irkutsk.ru/doc/order/186.pdf
3. Пальцев М.А. Персонифицированная медицина. Наука в России 2011; 1: 12–17. [Paltsev M.A. Personified medicine. Nauka v Rossii 2011; 1: 12–17. (In Russ.)]
4. Chadwick R., O’Connor A. Epigenetics and personalized medicine: prospects and ethical issues. Personalized Medicine 2013; 10(5): 463–471
5. Weston A.D., Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Prot Res 2004; 3(2): 179–196
6. Van Der Greef J., Hankemeier T., McBurney R.N. Metabolomics-based systems biology and personalized medicine: moving towards n=1 clinical trials? Pharmacogenomics 2006; 7(7): 1087–1094. DOI: 10.2217/14622416.7.7.1087
7. Heidecker B., Hare J.M. The use of transcriptomic biomarkers for personalized medicine. Heart Fail Rev 2007; 12(1): 1–11. DOI: 10.1007/s10741-007-9004-7
8. Морозов С.Л., Длин В.В., Сухоруков В.С., Воронкова А.С. Молекулярная нефропатология: новые возможности диагностики заболеваний почек. Российский вестник перинатологии и педиатрии 2017; 62(3): 32–36. [Morozov S.L., Dlin V.V., Sukhorukov V.S., Voronkova A.S. Molecular nephropathology: new opportunities for the diagnosis of kidney diseases. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2017; 62(3): 32–36. (In Russ.) DOI: 10.21508/1027-4065-2017-62-3-32-36
9. Игнатова М.С., Шатохина О.В. Диагностика и лечение нефротического синдрома у детей. Руководство для врачей. М.: МИА. 2009; 287. [Ignatova M.S., Shatokhina O.V. Diagnosis and treatment of nephrotic syndrome in children. A guide for doctors. Moscow: MIA, 2009; 287. (In Russ.)]
10. Ruf G., Lichtenberger A., Karle M., Haas P., Anacleto F., Schultheiss M. et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15: 722–732. DOI: 10.1097/01.asn.0000113552.59155.72
11. Schumacher V., Scharer K., Wubl E., Altrogge H., Bonzel K.E., Guschmann M. et al. Spectrum of early onset nephrоtic syndrome associated with WT1 missence mutations. Kidney Int 1998; 53: 1594–1600. DOI: 10.1046/j.1523-1755.1998.00948.x
12. Новиков П.В. Клинико-генетические варианты гипофосфатемического рахита. В кн.: Наследственные болезни органов мочевой системы у детей. Под ред. М.С. Игнатовой, В.В. Длина, П.В. Новикова. М.: Оверлей, 2014; 239– 262. [Novikov P.V. Clinical and genetic variants of hypophosphatemic rickets. In: Hereditary diseases of the organ of the urinary system in children. M.S. Ignatova, V.V. Dlin, P.V. Novikov (eds). Moscow: Overlay, 2014; 239–262. (In Russ.)]
13. Carpenter T., Imel E., Holm I., Jan M., Insogna K. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res 2011; 26(7): 1381–1388. DOI: 10.1002/jbmr.340
14. Gattineni J., Baum M. Genetic disorders of phosphate regulation. Pediatr Nephrol 2012; 27(9): 1477–1487. DOI: 10.1007/s00467-012-2103-2
15. Bergwitz C., Roslin N., Tieder M, Loredo-Osti J., Bastepe M., Abu-Zahra H. et al. SLC34A3 Mutations in Patients with Hereditary Hypophosphatemic Rickets with Hypercalciuria Predict a Key Role for the Sodium-Phosphate Cotransporter Na Pi-IIc in Maintaining Phosphate Homeostasis. Am J Hum Genet 2006; 78(2): 179–192. DOI: 10.1086/499409
16. Ruochen C., Aihua Z. Mechanisms of Glucocorticoid Resis- tance in Idiopathic Nephrotic Syndrome. Kidney Blood Press Res 2013; 37: 360–378. DOI: 10.1159/000350163
17. Warejko J.K., Tan W., Daga A. Whole Exome Sequencing of Patients with Steroid-Resistant Nephrotic Syndrome. Clin J Am Soc Nephrol 2018; 13(1): 53–62. DOI: 10.2215/CJN.04120417
18. Морозов С.Л., Длин В.В. К вопросу о стероидной терапии первичного нефротического синдрома у детей. Практическая медицина 2020; 18(3): 26–31. [Morozov S.L., Dlin V.V. On the issue of steroid therapy of primary nephrotic syndrome in children. Prakticheskaya meditsina 2020; 18(3): 26–31. (In Russ.)]
19. Bauer B., Hartz A.M.S., Fricker G., Miller D.S. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 2004; 66(3): 413–419. DOI: 10.1124/mol.66.3
20. Bauer B., Hartz A.M.S., Pekcec A., Toellner K., Miller D.S., Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 2008; 73(5): 1444–1453. DOI: 10.1124/mol.107.041210
21. Leopoldo M., Nardulli P., Contino M., Leonetti F., Luurtsema G., Colabufo N.A. An updated patent review on P-glycoprotein inhibitors (2011–2018). Expert Opin Ther Pat 2019; 29(6): 455–461. DOI: 10.1080/13543776.2019.1618273
22. Морозов С.Л. Значение экспрессии гена MDR1 у детей со стероид-зависимым нефротическим синдромом. Российский вестник перинатологии и педиатрии 2020; 65(4): 278. [Morozov S.L. Significance of MDR1 gene expression in children with steroid-dependent nephrotic syndrome. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2020; 65(4): 278. (In Russ.)]
23. Doaa Mohammed Youssef, Rabab Mohammed Elbehidy, Hosam Salah Abdelhalim, Ghada Elsyde Amr. Soluble Interleukine-2 Recptor and MDR1 Gene Expression Levels as Inflammatory Biomarkers for Prediction of Steroid Response in Children With Nephrotic Syndrome. Iranian J Kidney Dis 2011; 5(3): 154–176. DOI: 10.1111/j.1440-1797.2004.00340.x
24. Li Y., Hu X., Cai B., Chen J., Bai Y., Tang J. et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transpl Immunol. 2012; 27:12–18. DOI: 10.1016/j.trim.2012.03.006
25. Crettol S., Venetz J.P., Fontana M., Aubert J.-D., Ansermot N., Fathi M. et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics 2008; 18: 307–315. DOI: 10.1097FPC.0b013e3282f7046f
Review
For citations:
Dlin V.V., Morozov S.L. Personalized therapy in pediatric nephrology: Problems and prospects. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2021;66(2):6-12. (In Russ.) https://doi.org/10.21508/1027-4065-2021-66-2-6-12
Views:
650
Email this article 